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Objective: The eye represents a target site for GH action, although few data are available in patients with GH de-
ﬁciency (GHD). Our aimwas to evaluate central corneal thickness (CCT) and intraocular pressure (IOP) values in
GHD children to assess the role played by GHD or GH treatment on these parameters.
Design: In 74 prepubertal GHD children (51M, 23 F, aged 10.4± 2.4 years)wemeasured CCT and IOP before and
after 12 months of treatment. A baseline evaluation was also made in 50 healthy children matched for age, gen-
der and body mass index. The study outcome considered CCT and IOP during treatment and their correlations
with biochemical and auxological data.
Results: No difference in CCT and IOP between GHD children at baseline and controls was found (all
p N 0.005). GHD children after 12 months of therapy showed greater CCT (564.7 ± 13.1 μm) than
both baseline values (535.7 ± 17 μm; p b 0.001) and control subjects (536.2 ± 12.5 μm; p b 0.001),
with a concomitantly higher corrected mean IOP (15.6 ± 0.7 mm Hg; p b 0.001) than both baseline (12.5 ±
0.8mmHg; p b 0.001) and controls (12.3± 0.5mmHg; p b 0.001), without correlationwith auxological and bio-
chemical parameters.
Conclusions: 12 months of GH treatment in children with GHD, regardless of auxological and biochemical data,
affect CCT and IOP. Our ﬁndings suggest careful ocular evaluation in these patients to prevent undesirable side
effects during the follow-up.© 2014 Elsevier Ltd. All rights reserved.1. Introduction
Although the intrinsic mechanism of growth hormone (GH) actions
on eyes is still not fully known, it is well established that the eye repre-
sents a target site for GH action. GH may have endocrine, autocrine or
paracrine roles in ocular development and growth [1]. In this connec-
tion, GH is present in the human retina and vitreous ﬂuids [2] and
Harvey et al. identiﬁed GH immunoreactivity in the retina of chicks,
mice and rats, suggesting a role for GH in neurogenesis or ocular devel-
opment [3–5]. The role of GH in retinal function is supported by the
evidence of optic nerve and disc dysfunction in patients affected by
GH deﬁciency (GHD) [6,7]. Many years ago it was suggested that GH
might facilitate a condition of glaucoma, demonstrated by higher GH
levels after intravenous arginine administration in patients with open-
angle glaucoma than in control subjects, supporting the hypothesis, Diabetology and Metabolism,
cine (Di.Bi.M.I.S.), University of
.: +39 091 6552109; fax: +39
.that increased plasma GH levels may interfere with regulation of ocular
pressure [8]. In addition, the importance of GH action in ocular develop-
ment is demonstrated by the ocular abnormalities that can occur in
patients with pituitary GH excess or deﬁciency [7,9–12]. Elevated intra-
ocular levels of insulin growth factor-I (IGF-I) in acromegalic patients
have previously been reported [11] while in patients with primary GH
insensitivity treatedwith IGF-I therapy, a greater average ocular dimen-
sion, including the average corneal curvature, than that observed in un-
treated patients has been demonstrated, further supporting the effect of
IGF-I on ocular growth [13]. The only study that performed a complete
ocular evaluation, including the measurement of central corneal thick-
ness (CCT) and intraocular pressure (IOP), in children affected by GHD
already under GH-treatment, concluded that an increased CCT, probably
associated with a shorter axial length, can represent a sign of a delayed
growth of the eye in these patients [14]. In addition, more recently
Youngster et al. showed increased IOP in GH-treated children [15].
However, to the best of our knowledge, CCT and IOP have never been
prospectively assessed in GHD patients, i.e. before and after GH treat-
ment. The aim of this study was to evaluate CCT and IOP values in
children with isolated idiopathic GHD at before and after 12 months
of GH therapy.
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2.1. Patients
For the purpose of this study, 74 consecutive children (51males and
23 females, mean age 10.4 ± 2.4 years) affected by newly diagnosed
isolated idiopathic GHD coming to the Units of Endocrinology of the
University of Palermo from Jan 1st 2010 to December 31st 2012 were
prospectively enrolled. Fifty healthy children, matched for age (mean
age 11± 2.6 years), gender and bodymass index (BMI), were recruited
as controls among the siblings of the patients and the children of med-
ical and paramedical personnel of the Department and their relatives.
All children evaluated were in the 1st stage of sexual development
according to the criteria of Marshall and Tanner [16]. The diagnosis of
GHD was established by the clinical, auxological and biochemical
criteria of the GH Research Society [17]. All patients underwent IGF-I
assessment, an insulin tolerance test (ITT) and a GHRH plus arginine
(GHRH-Arg) test. GHD was demonstrated by the failure of GH to
respond to the two stimuli, with GHpeaks below10 and 20 μg/l, respec-
tively. The subjects with a diagnosis of GHD received GH once daily at
bedtime with a pen injection system. The initial daily dose was
0.025 mg/kg. During the study, the GH dose administered was adjusted
in order to maintain serum IGF-I levels within the normal range for age,
with a maximum dose of 0.035 mg/kg. Children with a therapy follow-
up of less than 12 months were excluded from this analysis. Similarly,
children with already known ocular clinically relevant disease, severe
refractive errors, or family history of ocular hypertension or glaucoma
were excluded from the analysis.
2.2. Study design
This was an analytical, prospective study to analyze CCT and IOP and
their relationship with biochemical and auxological data in GHD
children. In all subjects, according to our ﬁxed internal protocol, we
measured body height (standard deviation, SD), body mass index
(BMI) and bone age. We calculated the ratio between the bone age
and the chronological age (normal = 1) and we showed the data as a
bone/chronological age ratio. All subjects underwent ophthalmological
evaluation, including measurement of CCT and IOP by applanation to-
nometry. GHD childrenwere evaluated at baseline and after 12 months
of GH treatment, while controls were evaluated once at baseline. The
study outcome considered CCT and IOP during treatment and their
correlations with biochemical and auxological data. The Institutional
Ethics Committee of the University of Palermo approved this study. At
the time of ﬁrst observation, an informed consent for the scientiﬁc use
of the data was obtained from parents. This research has followed the
Tenets of the Declaration of Helsinki.
2.3. Ocular evaluation
CCT was measured by very high-frequency ultrasonic contact
pachimetry (Pachpen Accutome 24-5100) after local anesthetic instilla-
tion, with a sound velocity of 1640m/s and a mean accuracy of ±5 μm.
The value of CCT was performed taking the average of ﬁve consecutive
pachimetry measurements.
IOPwasmeasured bymeans of Goldmann applanation tonometry. A
single ophthalmologist performed both examinations in all children.
We showed the CCT and IOP values as the average from both eyes.
2.4. Hormone and biochemical assays
During the entire study period, in our centralized laboratory the GH
levels were assayed by immunoradiometric assays (Radim, Pomezia,
Italy), with an assay sensitivity of 0.05 μg/l. The intra-assay coefﬁcients
of variation (CV) were 2.5–3.9% and the inter-assay CV were 3.8–5.0%.
Serum total IGF-I was assayed in the same laboratory with the ELISAmethod (OCTEIA IGF-I kit, IDS Inc., Fountain Hills, AZ, USA). The sensi-
tivity of the method was 1.9 μg/l. The inter- and intra-assay CV values
were 7–7.1 and 2.3–3.5% respectively, at IGF-I levels of 90.7–186 and
66.7–120.9 μg/l respectively. The normal ranges (males and females
combined) of total IGF-I levels (μg/l) were the following: 12–108
(0–1 years); 13–100 (1–3 years); 26–280 (3–6 years); 85–230
(6–9 years); 98–404 (9–12 years); 142–525 (12–15 years); and
146–415 (15–20 years).
2.5. Statistical analysis
The Statistical Packages for Social Sciences SPSS version 17 was
used for data analysis. Baseline characteristics were presented as
mean ± standard deviation (SD) for continuous variables; rates
and proportions were calculated for categorical data. Normality of distri-
bution for quantitative variables was assessed with the Kolmogorov–
Smirnov test. Differences between continuous variables were analyzed
using the Mann–Whitney U-test, while differences between categorical
variables were analyzed by using the χ2-test and Fisher's exact test,
when appropriate. Differences between paired continuous variables in
the GHD group (before and after 12 months of therapy) were analyzed
using the Wilcoxon test. Correlations among continuous variables with-
out normal distribution were determined using Spearman's test (non-
parametric equivalent for Pearson test). A p value b0.05 was considered
statistically signiﬁcant.
3. Results
All clinical and biochemical features of GHD children and control
subjects are shown in Table 1.
3.1. GHD subjects at baseline vs. control subjects
Height, bone age, GH and IGF-I levels were signiﬁcantly lower in
GHD subjects than controls, as expected (Table 1). No signiﬁcant differ-
ence in mean CCT values (535.7 ± 17 vs. 536.2 ± 12.5 μm; p= 0.859)
was found (Fig. 1A). Similarly, no difference was found in IOP values
(12.5 ± 0.8 vs. 12.3 ± 0.5 mm Hg; p = 0.118) between the two
groups.
3.2. GHD subjects after 12 months of GH therapy vs. baseline
A signiﬁcant increase in height, BMI and bone age was documented
in GHD children after 12 months of therapy, as expected. Similarly, IGF-
1 levels showed a signiﬁcant increase (251.8± 100.8 vs. 90.34± 39.34;
p b 0.001) in all GHD subjects from baseline to 12 months of therapy.
The analysis of the ocular parameters showed a signiﬁcant increase
in mean CCT values (564.7 ± 13.1 vs. 535.7 ± 17 μm; p b 0.001) in
GHD children after 12 months of GH therapy than baseline values
(Fig. 1B), with a concomitantly higher corrected mean IOP (15.6 ± 0.7
vs. 12.5 ± 0.8 mm Hg; p b 0.001).
No signiﬁcant correlations among CCT at 12 months or the variation
(delta) of CCT from baseline to 12 months of treatment and auxological
(height SD, height velocity SD, BMI, bone age) and biochemical param-
eters (IGF-I SD) after 12 months or their delta were found (all p N 0.05;
data not shown). Conversely, a signiﬁcant inverse correlationwas found
between baseline CCT and its delta (Rho−0.656; p b 0.001). Grouping
all children into those with lower (bthe median value of 534 μm) and
greater (≥the median value of 534 μm) baseline CCT, we found no sig-
niﬁcant difference in auxological and biochemical parameters (data not
shown).
3.3. GHD subjects after 12 months of GH therapy vs. control subjects
GHD children after 12 months of therapy showed similar BMI, bone/
chronological age ratio and IGF-I levels compared to control subjects (all
Table 1
Clinical, biochemical and ocular parameters of children affected by growth hormone deﬁciency (GHD) at baseline and after 12 months of GH treatment and control subjects.
GHD subjects at baseline
(No. 74)
GHD subjects after 12 months
of treatment (No. 74)
Control subjects
(No. 50)
p p⁎ p⁎⁎
No. (%) No. (%) No. (%)
Gender – 0.752 –
Males 51 (68.9) – 32(64)
Females 23 (31.1) – 18(36)
Mean ± SD Mean ± SD Mean ± SD
Height (SD) −2.12 ± 0.74 −1.66 ± 0.73 − 0.35 ± 0.31 b0.001 0.015 b0.001
BMI (kg/m2) 17.5 ± 3.2 18.3 ± 3.1 18 ± 2.3 b0.001 0.730 0.560
Bone age (yrs) 8.8 ± 2.9 10.8 ± 2.3 10.6 ± 2.2 b0.001 0.008 0.629
Bone/chronological age ratio 0.79 ± 0.11 0.90 ± 0.06 0.97 ± 0.10 b0.001 0.016 0.090
IGF-I (μg/l) 90.34 ± 39.34 251.8 ± 100.8 231.36 ± 88.72 b0.001 b 0.001 0.247
Basal GH (μg/l) 0.47 ± 0.64 – 4.44 ± 2.16 – b 0.001 –
Peak GH during ITT (μg/l) 3.15 ± 2.80 – 16.23 ± 5.12 – b 0.001 –
Peak GH during GHRH plus arginine test (μg/l) 9.32 ± 6.08 – 32.44 ± 8.33 – b 0.001 –
Mean central corneal thickness (μm) 535.7 ± 17 564.7 ± 13.1 536.2 ± 12.5 b0.001 0.859 b0.001
Corrected mean intraocular pressure (mm Hg) 12.5 ± 0.8 15.6 ± 0.7 12.3 ± 0.5 b0.001 0.118 b0.001
p = difference between GHD subjects at baseline and GHD subjects after 12 months of treatment.
p⁎ = difference between GHD subjects at baseline and control subjects.
p⁎⁎ = difference between GHD subjects after 12 months of treatment and control subjects.
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p b 0.001).
When we compared the ocular parameters of GHD children after
12 months of therapy with those of control subjects, we found a
signiﬁcant difference in mean CCT (564.7 ± 13.1 vs. 536.2 ± 12.5 μm;
p b 0.001) and corrected IOP (15.6 ± 0.7 vs. 12.3 ± 0.5 mm Hg;
p b 0.001).
4. Discussion
In this study, aimed to evaluate whether CCT in GHD children is
mainly determined by the condition of untreated GHD or by effects of
exogenous GH, we found that 12 months of GH treatment signiﬁcantly
increase CCT and IOP valueswhen comparedwith pre-treatment values.
We calculated correction values for IOP readings for CCT according
to Doughty's meta-analysis [18]. In this connection, it is known that
CCT can signiﬁcantly affect IOP readings obtained using different mea-
surement techniques, with conﬂicting conclusions. Normally hydrated,
thicker corneas lead to higher IOP readings and thinner corneas to
lower readings. Several studies in adults showed a lower CCT in some
cases of normal-tension glaucoma and a higher CCT in cases of ocular
hypertension [18,19]. For this reason, to determine an accurate value,
IOP should always correct for CCT.
GH and IGF-I are known to be involved in ocular development [20].
The growth of the eye seems to play a role in the reduction of corneal
thickness in the ﬁrst years of life. Indeed, CCT in premature infants is
greater than in full-term newborns and in the latter is signiﬁcantly
greater than in adults [21,22]. CCT in normal children from the age of
3 is similar to those reported in adults [21]. Normal subjects were
found to show an average CCT of 515 ± 33 μm, with a signiﬁcant de-
creasewith age of 45 μmper decade [23]. In normal children the average
CCT was found to be ranging from 529 to 555 μm [24−26], with a close
correlation with values reported for adults [26]. In addition, CCT
values appear stable over time and show a positive correlation with
IOP [27,28].
Most of the studies performed on patients with alterations of the
GH-IGF-I axis were limited to assessing the differences in the ocular
parameters between GH or IGF-I-treated patients, untreated ones, and
controls, without a prospective evaluation during the follow-upof treat-
ment. Indeed, it is unclear whether the effect on the eye was caused by
the GHD condition or GH treatment.
In this study, we decided to perform an ocular evaluation in GHD
children before the onset of GH treatment and prospectively after
12 months, to highlight the role of the condition of hormone deﬁciency
or GH treatment on CCT and IOP. The control group was evaluated onceat baseline and this can be considered a limit of the study. However, we
decided to perform the ocular evaluation in control subjects only once
because the evidence that CCT in normal children, in the absence of
any pathology, normally does not change over time [21].
We found that there is no difference in CCT and IOP between un-
treated GHD children and control subjects and this ﬁnding apparently
contrasts with the few existing data in the literature [14]. Indeed,
Parentin et al. showed that a greater CCT, associated with a shorter
axial length, can represent a sign of delayed growth of the eye in GHD
children [14,29]. However, the authors did not prospectively evaluate
GHD children during GH treatment, but analyzed the ocular parameters
in a group of patients already under GH treatment, and this bias could
explain the different results. To reinforce this hypothesis, in our cohort
of patients after 12 months of GH treatment a signiﬁcant increase in
CCT was observed. Therefore, GH treatment, and not the condition of
GHD, seems to affect the ocular parameters evaluated. This ﬁnding is
in line with the evidence that signiﬁcantly higher values of CCT were
found a few years ago in thirteen patients with acromegaly compared
to that of the control group [9], suggesting a more important role of
GH on the eye. Indeed, the effects of exogenous GH on synthesis of the
extracellular matrix of sclera have been demonstrated [20]. In addition,
the evidence that acromegalic patients with longer active and uncon-
trolled disease showed greater CCT values supported the hypothesis
that GH may have stimulatory effects on the cornea as well as on
other target organs. Similarly, in our patients IOP too is affected by GH
treatment, in line with the data of Youngster et al., which showed an
increase in mean IOP in GH treated children [15]. The hypothesis that
the effect of GH on CCT is played through the rehydrating effect of GH
treatment can not be ruled out [30,31].We agree with the conclusion
of Youngster et al. that the clinical signiﬁcance of the increase in IOP
in these patients is unclear [15], as the IOP values recorded in our pa-
tients, even higher than baseline and control values, were still within
the normal range [32]. Therefore, to date, the clinical consequences of
the already known effect of GH on CCT and IOP, such as the risk of devel-
oping glaucoma, are likely only potential. We speculate that, based on
the demonstrated effect of GH on CCT and on the effect of CCT on the
IOP, the usefulness of a complete ocular evaluation, including the CCT
measurement, in children who are under GH replacement treatment
also for many years, is to make a correct diagnosis and any proper man-
agement of potential ocular hypertension in these patients, especially
when their CCT markedly differs from the normal values. In this study
children have been evaluated for a follow-up of only 12 months, show-
ing an increase in CCT and consequently in IOP, although it remains in
the normal range. However, with these data in mind, a longer period
of GH therapy could probably further increases these values. In addition,
Fig. 1. Difference inmean central corneal thickness (CCT) among childrenwith growth hormone deﬁciency (GHD) at baseline, before the start of GH treatment, and control subjects (1A)
and difference in CCT before and after 12 months of GH treatment in GHD children (1B).
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of ocular hypertension or overt glaucoma, we can speculate that a full
ocular assessment should be especially done in case where there is a
positive family history.
The absence of correlation between CCT and biochemical data could
be explained with the evidence that all subjects enrolled in this study
underwent a similar GH dose, between 0.025 to 0.035 mg/kg during
the study, in order to maintain serum IGF-I levels within the normal
range. Prospective large-scale studies aiming to consider the possible
role of different GH doses on CCT changes could better clarify the effect
of GH on corneal thickness. In addition, it would be interesting to
perform a re-evaluation of ocular parameters after the discontinuation
of GH to understand whether the abovementioned changes in CCT
and IOP are reversible or not. For this reason, we will plan a careful oc-
ular examination in all children after the discontinuation of therapy.
Instead, the baseline CCT value seems to be a determinant for how the
cornea reacts to GH replacement therapy. Curiously, children with
lower CCT at baseline showed a greater increase in CCT after 12 months
of GH therapy although this ﬁnding, in our opinion, does not seem to
have a great clinical relevance. In fact,we foundno signiﬁcant difference
in auxological or biochemical parameters between GHD children with
lower and greater baseline CCT.
In conclusion, our data demonstrated that 12 months of GH treat-
ment in children with GHD, regardless of auxological and biochemical
data, affect corneal thickness and IOP. With this in mind, our ﬁndings
suggest careful ocular evaluation in GHD children during GH treatment,
with CCT and IOP measurements, to prevent the potential risk of unde-
sirable side effects during the follow-up.
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